Clinical trial
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
NCT00947193 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
- Lead sponsor
- PTC Therapeutics
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 14, 2009
- Completion date
- August 30, 2011
- Enrollment
- 13 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.